Key Insights

Highlights

Success Rate

78% trial completion

Published Results

28 trials with published results (19%)

Research Maturity

54 completed trials (37% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.2%

15 terminated out of 147 trials

Success Rate

78.3%

-8.3% vs benchmark

Late-Stage Pipeline

3%

5 trials in Phase 3/4

Results Transparency

52%

28 of 54 completed with results

Key Signals

28 with results78% success15 terminated

Data Visualizations

Phase Distribution

105Total
Not Applicable (42)
Early P 1 (1)
P 1 (36)
P 2 (21)
P 3 (3)
P 4 (2)

Trial Status

Completed54
Recruiting41
Terminated15
Unknown14
Active Not Recruiting10
Not Yet Recruiting6

Trial Success Rate

78.3%

Benchmark: 86.6%

Based on 54 completed trials

Clinical Trials (147)

Showing 20 of 20 trials
NCT01109394Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT03470285Not ApplicableCompletedPrimary

Multiparametric MRI for Diagnosing Small Renal Tumors

NCT00458536Phase 1CompletedPrimary

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

NCT03693014Phase 2Active Not Recruiting

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

NCT07341737Phase 1Recruiting

SL-28 for Advanced Solid Tumours

NCT05873686Phase 1Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

NCT01582204Not ApplicableActive Not RecruitingPrimary

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

NCT07227415Phase 1Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT01888198Active Not RecruitingPrimary

Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

NCT00026884Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT05820087Not ApplicableActive Not RecruitingPrimary

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT06967961Not ApplicableRecruiting

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NCT07636148Not Yet Recruiting

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

NCT03289962Phase 1Completed

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

NCT07610083Not Yet Recruiting

A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer

NCT05225428Not ApplicableRecruiting

Video Education With Result Dependent dIsclosure

NCT06852638Phase 2RecruitingPrimary

CD70-targeted immunoPET Imaging of Malignant Cancers

NCT06116253Not ApplicableActive Not RecruitingPrimary

Advanced Diffusion Imaging in Renal Cancer Patients

NCT06239194Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06760702Phase 2Terminated

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers

Scroll to load more

Research Network

Activity Timeline